PharmNovo is pleased to announce the appointment of Olof Breuer MD, PhD, Specialist in Clinical Pharmacology, who will be acting as our Chief medical officer.
Olof has over 25 years of experience in Pharmaceutical R&D, where of 17 years within big and small pharmaceutical companies. He has held positions as medical adviser, principal scientist, project manager and clinical pharmacology director. Areas of expertise span through preclinical R&D, translational sciences, and clinical development, including clinical evaluation of in-licensing opportunities.
As trained pharmacokineticist, he has routinely developed and utilised modelling and simulation techniques to facilitate studydesign and data evaluation. At present, he is based at the Clinical trials unit/Department of clinical pharmacology at Karolinska university hospital.
PharmNovo is pleased to announce the appointment of Olof Breuer MD, PhD, Specialist in Clinical Pharmacology, who will be acting as our Chief medical officer.
Olof has over 25 years of experience in Pharmaceutical R&D, where of 17 years within big and small pharmaceutical companies. He has held positions as medical adviser, principal scientist, project manager and clinical pharmacology director. Areas of expertise span through preclinical R&D, translational sciences, and clinical development, including clinical evaluation of in-licensing opportunities.
As trained pharmacokineticist, he has routinely developed and utilised modelling and simulation techniques to facilitate studydesign and data evaluation. At present, he is based at the Clinical trials unit/Department of clinical pharmacology at Karolinska university hospital.
CTC AWARDED AS CRO
It is with pleasure that we can announce that Clinical Trial Consultants AB (CTC)
Read more →CANADA PATENT GRANT
We are pleased to announce that PharmNovo AB has been granted a patent for our candidate PN6047 in Canada. Previously patent has been granted in the USA, the EU, Japan, Australia and China. Canada was the last major country remaining for PN6047.
Read more →A stronger team
We are pleased to announce that we have hired Jesper Kjerulff, starting on June 1st, to serve as the project leader for the continued development of our candidate compound PN6047 and lead the project into phase 1 clinical trials in Q2 2022.
Read more →In memory of Hans G.
Hans G. Nilsson, PhD (1943–2021), has during a cross country ski trip on a beautiful Sunday in January 2021, unexpectedly left us in grief and mourning.
Read more →
